[Infliximab in the treatment of patients with Crohn's disease: preliminary report].

Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation.

Aim: To assess the effectiveness of Infliximab in patients with Crohn's disease.